Minerva Surgical, Inc. UTRS

Company Overview

Minerva Surgical, Inc. (formerly Nasdaq: UTRS) is a medical technology company focused on women’s health, specifically the treatment of abnormal uterine bleeding (AUB) and related gynecologic conditions. The company develops and commercializes minimally invasive surgical solutions used by gynecologists in outpatient and hospital settings. Its products are primarily designed for endometrial ablation and intrauterine tissue removal procedures, serving physicians and healthcare systems seeking alternatives to more invasive hysterectomy procedures.

The company’s principal revenue drivers historically included its endometrial ablation systems and related disposable products. Key offerings have included the Minerva ES Ablation System, the Genesys HTA System, and the Symphion Tissue Removal System. Minerva Surgical positioned itself within the broader women’s health and minimally invasive surgery markets by emphasizing procedural efficiency, reduced recovery times, and office-based treatment capabilities. The company was founded in 2008 and later became publicly traded before subsequently undergoing strategic and corporate changes following operational and financial pressures reported in public filings. Public information regarding the company’s current standalone operating status is limited, and some recent ownership and operational details are inconclusive based on available public sources.